Thus, we assessed the impact of NEK2 inhibition on CDK4/6i response, in vivo using the selective NEK2 inhibitor (NEK2i), NBI-961 (49), in three different breast cancer models. This evidence concerns the gene CDK4 and breast carcinoma.